Endothelin-1/endothelin-3 Ratio: a Potential Prognostic Factor of Pulmonary Arterial Hypertension
Overview
Authors
Affiliations
Background: Pulmonary arterial hypertension (PAH) is a rare condition characterized by elevated pulmonary artery pressure leading to right-heart failure and death. Endothelin (ET)-1 has been shown to play a significant pathogenic role in PAH. ET-3 has not yet been investigated in PAH.
Methods: ET-1 and ET-3 plasma concentrations were measured in 33 PAH patients prior to any specific PAH therapy and in 9 control subjects. In PAH patients, hemodynamic parameters measured by right-heart catheterization, 6-min walk distance (6MWD), New York Heart Association (NYHA) functional class, and time until lung transplantation or death were recorded.
Results: In patients with PAH, levels of ET-1 were increased while those of ET-3 were decreased, as compared to control subjects (p < 0.005 for both comparisons). ET-1/ET-3 ratio varied little in control subjects, while it increased threefold in PAH patients (p < 0.0001). ET-1 correlated positively with right atrial pressure (RAP), indexed total pulmonary resistance, and negatively with cardiac index and venous saturation of oxygen (Svo(2)). ET-3 correlated positively with 6MWD. ET-1/ET-3 ratio correlated positively with RAP, negatively with Svo(2) and 6MWD, and was also associated with NYHA functional class. ET-1/ET-3 ratio was associated with prognosis in this sample of PAH patients treated with specific therapies.
Conclusions: PAH is characterized by elevated ET-1 and ET-1/ET-3 ratio and decreased ET-3 plasma concentrations. All of them correlate with hemodynamic and clinical markers of disease severity. ET-1/ET-3 ratio might be a novel prognostic factor in PAH. These preliminary data should be validated in a large prospective multicenter cohort of PAH patients.
Niiyama S, Nakashima T, Ueno K, Hirahara D, Nakajo M, Madokoro Y Cureus. 2024; 16(7):e65783.
PMID: 39082048 PMC: 11288644. DOI: 10.7759/cureus.65783.
Myronenko O, Foris V, Crnkovic S, Olschewski A, Rocha S, Nicolls M Eur Respir Rev. 2023; 32(167).
PMID: 36631133 PMC: 9879331. DOI: 10.1183/16000617.0173-2022.
Lago-Docampo M, Solarat C, Mendez-Martinez L, Baloira A, Valverde D Front Cardiovasc Med. 2022; 9:823133.
PMID: 35282351 PMC: 8913939. DOI: 10.3389/fcvm.2022.823133.
Pulmonary hypertension: Proteins in the blood.
Wilkins M Glob Cardiol Sci Pract. 2020; 2020(1):e202007.
PMID: 33178814 PMC: 7592080. DOI: 10.21542/gcsp.2020.7.
Yoshida T, Matsuura K, Goya S, Ma D, Shimada K, Kitpipatkun P Exp Ther Med. 2020; 20(6):149.
PMID: 33093887 PMC: 7571338. DOI: 10.3892/etm.2020.9278.